in some trials, the incidence was more than 10% higher compared to placebo [14]
In 2023, branded obesity drug sales reached $6 billion, and this figure is expected to grow exponentially as demand continues to rise and these medications are used to treat a broader range of diseases
Furthermore, whereas sex-specific effects of GLP-1 have been reported for its metabolic outcomes and reward behaviors (28,29,58), research revolving GLP-1s effects on cognition and neuroprotection have been conducted mainly in males
Start your intake Clinical Evidence for Non-Diabetic GLP-1 Use The STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) enrolled primarily non-diabetic adults with obesity
Kidney Concerns: Dehydration from gastrointestinal side effects can occasionally affect kidney function
Youve taken an important step by adding Lantus to your diabetes treatment plan